Imugene wins Chinese Linguet patent
01 May, 2013 by Dylan Bushell-EmblingImugene (ASX:IMU) has secured its second patent from an Asian market protecting the use of its Linguet drug-delivery technology for formulations of drugs to prevent bone loss.
Australian biotech sector grew 7% in 2012
01 May, 2013 by Dylan Bushell-EmblingRevenue from the world’s major biotech markets grew 8% in 2012, but weak R&D spending growth is a sign that the sector has still not fully recovered from the GFC, says Ernst & Young.
pSivida partner launches Iluvien in the UK
01 May, 2013 by Dylan Bushell-EmblingAlimera has launched Iluvien, the intravitreal implant designed by pSivida (ASX:PVA), into the UK market.
ResMed posts record profit for March quarter
30 April, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) grew its March-quarter profit by 31% and revenue by 10%, thanks to strong gains in the Americas region.
Public consultations on Asian Century country strategies
30 April, 2013Australia’s position in the Asia-Pacific region, in what has been dubbed the Asian Century, means biotechnology is poised in the right industry in the right region.
Elastic patch supports cardiac cell growth
30 April, 2013Scientists are a step closer to being able to repair damaged human heart tissue thanks to a world-leading research collaboration between the University of Sydney and Harvard University.
STA cleared to market C. difficile treatment
26 April, 2013 by Dylan Bushell-EmblingSpecialised Therapeutics Australia has won approval to market fidaxomicin - the C. difficile treatment licensed from Optimer Pharmaceuticals - in Australia.
Registrations open for AusBiotech 2013
26 April, 2013The biggest Australian biotechnology event for the year, the AusBiotech 2013 national conference, will be held from 29 October-1 November in Brisbane. Registrations are now open.
ResMed launches home COPD treatment
26 April, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has launched the first FDA-approved home VPAP COPD treatment device into the US market.
Phylogica granted EU Phylomer patent
25 April, 2013 by Dylan Bushell-EmblingPhylogica (ASX:PYC) has received a European patent covering the use of Phylomer peptides from its libraries to treat ischemic conditions including stroke and ARDS.
Prima names new advisors for CVac programs
24 April, 2013 by Dylan Bushell-EmblingPrima BioMed (ASX:PRR) has appointed oncology experts Dr Holbrook Kohrt and Dr Pamela Klein as clinical advisors for its cancer vaccine programs.
Pharmaxis shares plunge on new Bronchitol setback
24 April, 2013 by Dylan Bushell-EmblingPharmaxis (ASX:PXS) has revealed a phase III trial of Bronchitol in bronchiectasis failed to meet its primary goal, sending its share price falling 45%.
Registration deadline looming for R&D Tax Incentive
23 April, 2013The registration of research and development (R&D) activities, under the R&D Tax Incentive, closes next week for the 2011-12 year.
Bionomics initiates manufacturing of tumour drug
23 April, 2013 by Dylan Bushell-EmblingBionomics (ASX:BNO) has contracted Lonza to produce tumour drug candidate BNC101 ahead of clinical trials anticipated for 2014.
Alchemia lands discovery deal with AstraZeneca
23 April, 2013 by Dylan Bushell-EmblingAlchemia (ASX:ACL) has entered a small molecule drug discovery collaboration with AstraZeneca based on the former’s VAST chemistry platform.
